Interview: Acacia Seeks Access All Areas For PONV Drug Barhemsys
Third Time Lucky With FDA Approval
Acacia's bids to get the thumbs-up in the US for its post-operative nausea and vomiting therapy have finally borne fruit. CEO Mile Bolinder tells Scrip that his experienced team is now firmly focused on gaining as many hospital formulary approvals as possible for Barhemsys.
